SmartBreast ™ Pronounces Molecular Breast Imaging Partnership with FITI

PITTSBURGH, February 9, 2021 / PRNewswire / – After acquiring Molecular Breast Imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast ™), a privately held company focused on breast cancer prevention and diagnosis, announced today their establishment known a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) for the production of MBI systems (Molecular Breast Imaging).

FITI is excited to partner with SmartBreast to provide MBI for earlier cancer detection in women with dense breasts.

Tweet this

EVE CLEAR SCAN ™ e750 (left) and e680 (right) are manufactured by FITI for SmartBreast ™.

FITI has made significant investments in SmartBreast and will be the contract manufacturer for two MBI systems recently acquired by SmartBreast: the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. SmartBreast will rename the two systems to “EVE CLEAR SCAN ™” e750 and e680. SmartBreast and FITI will jointly develop and manufacture innovative, cost-effective, next-generation MBI systems to further enhance the effectiveness of early-stage cancer detection. We will incorporate stereotactic MBI guided biopsy and 3D MBI technology to further improve functionality.

MBI saves lives by earlier detection of breast cancer in women with dense breasts, which comprises approximately 40% of American, European, and African women and 70% of Asian women. MBI sees through dense breast tissue and finds cancers that mammograms lack. In a published clinical study1 with a one-year follow-up of 1,585 women with dense breasts, researchers at the Mayo Clinic reported that mammograms found 3.2 cancers per 1,000 women with dense breasts. Adding low-dose MBI increased the number of cancers found to 12 per 1,000.

“FITI is excited to partner with SmartBreast to help women around the world detect cancer in dense breast tissue earlier,” he says Kevin Chiu, CEO and President of FITI. “We are proud to invest in and work with SmartBreast to deliver highly effective MBI systems to women around the world.”

According to Dr. James Hugg, CEO and President of SmartBreast: “We are pursuing a strategy to make SmartBreast the largest global player in the secondary screening and diagnostics market for women with dense breasts by providing the most effective tool for the localization and diagnosis of cancers that are affected by We have acquired the Dilon Technologies D6800 and the Discovery NM from GE Healthcare 750b MBI product lines consolidating clinically proven reliable products with 217 installations worldwide. SmartBreast, in partnership with our manufacturing partner, FITI, will make MBI available to all dense breast patients in desperate need of better cancer detection and diagnosis tools. “

Contact Dr. Hugg ([email protected]) via MBI or the investment in SmartBreast, which a $ 5 million SEED financing round.

  1. DJ Rhodes et al., American Journal of Roentgenology 2015, 204: 241- 251.

About SmartBreast Corporation:
SmartBreast Corp. is privately owned and has its headquarters nearby Pittsburgh and offices in The angel and Taipei, Taiwan (eveclearscan.com and smartbreast.com are under construction). It is a privately owned subsidiary of EVO WorldWide, LLC (evo-worldwide.com) that sells MBI worldwide. SmartBreast was founded in 2019 by Bradley stalemate, PhD (CEO, The angel), Prof. Chin-tu chen, PhD (Deputy Chairman of the Board, Chicago), and James Hugg, PhD (CEO, Pittsburgh), each with 30 years of medical imaging experience. SmartBreast manufactures Molecular Breast Imaging (MBI) scanners for dense breasts under the brand name EVE CLEAR SCAN ™, which are trademarks of SmartBreast Corporation along with SmartBreast ™, EVE SCAN ™ and the EVE Owl logo.

SOURCE Smart Breast Corporation

related links

https://smartbreast.com

Comments are closed.